Author:
Lucero Kana T,Yoo James,Ramamurthy Chethan, , ,
Funder
This article is published under the Creative Commons Attribution Non-commercial License.
Publisher
Touch Medical Media, Ltd.
Reference56 articles.
1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts. Bladder Cancer. SEER, 2018. Available at: www.seer.cancer.gov/statfacts/html/urinb.html (accessed 4 October 2022).
2. Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404–23.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
4. Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. J Urol. 1988;139:475–7.
5. Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer. 2014;38:80–108.